Status:
COMPLETED
Neurofeedback for Obsessive-Compulsive Disorder (OCD)
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The aim of this study is to train patients with obsessive-compulsive disorder to control a region of their brain that has been associated with their symptoms. Patients in the experimental group will b...
Detailed Description
Original study design recruiting controls who were matched to the experimental group was changed to a randomized design prior to enrollment of the first participant.
Eligibility Criteria
Inclusion
- Primary Diagnosis of Current OCD, based on Diagnostic and Statistical Manual (DSM-IV) criteria, a Y-BOCS (Yale-Brown Obsessive-Compulsive Scale) score \>=16
- Principle OCD symptoms- Primary symptoms must be either Cleaning/Contamination or Checking; other symptoms okay
- Unmedicated (or medications stable for 8 weeks).
- Research group must be able to identify a target region in the orbitofrontal cortex that is related to symptoms
Exclusion
- Active Psychosis; Pervasive Developmental Disorder ; epilepsy or other major neurological disorder
- History of major head trauma or psychosurgery
- Active Substance Abuse within 6 months
- Seizure disorder or other significant neurological disorder
- Active Suicidality
- Pregnancy
- severe claustrophobia, ferromagnetic metal in the body, a pacemaker or defibrillator, or any other condition that would make MRI scanning unsafe or inappropriate
- any psychotropic medication other than a selective serotonin reuptake inhibitor (SSRI) antidepressant, anafranil, or a low-dose hypnotic or anxiolytic taken on an as-needed basis
- active cognitive/behavioral therapy initiated within the last 3 months (continuation of established maintenance therapy that has been going on for longer than 3 months will not be grounds for exclusion)
Key Trial Info
Start Date :
July 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT02206945
Start Date
July 1 2015
End Date
November 1 2021
Last Update
February 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University School of Medicine
New Haven, Connecticut, United States, 06520